At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Apr 1, 2026 at 21:48 ET
Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising approximately $300 million in gross proceeds. The company may sell an additional 1,551,750 shares via an underwriter option, and plans to use the funds for commercial readiness of barzolvolimab, clinical development, and general corporate purposes.
- Celldex is offering 10,345,000 shares at $29.00 per share.
- Gross proceeds expected: ~$300 million (excluding underwriter option).
- Underwriters have a 30-day option to purchase up to 1,551,750 additional shares.
- Proceeds will fund commercial launch of barzolvolimab (if approved), clinical development, platform expansion, and general corporate needs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access